Literature DB >> 23861223

Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia.

Stéphanie Poulain1, Christophe Roumier, Sylvie Galiègue-Zouitina, Agnès Daudignon, Charles Herbaux, Rachid Aiijou, Amélie Lainelle, Natacha Broucqsault, Elisabeth Bertrand, Salomon Manier, Aline Renneville, Valérie Soenen, Sabine Tricot, Catherine Roche-Lestienne, Patrick Duthilleul, Claude Preudhomme, Bruno Quesnel, Pierre Morel, Xavier Leleu.   

Abstract

SNP array (SNPa) was developed to detect copy number alteration (CNA) and loss of heterozygosity (LOH) without copy number changes, CN-LOH. We aimed to identify novel genomic aberrations using SNPa in 31 WM with paired samples. Methylation status and mutation were analyzed on target genes. A total of 61 genetic aberrations were observed, 58 CNA (33 gains, 25 losses) in 58% of patients and CN-LOH in 6% of patients. The CNA were widely distributed throughout the genome, including 12 recurrent regions and identified new cryptic clonal chromosomal lesions that were mapped. Gene set expression analysis demonstrated a relationship between either deletion 6q or gain of chromosome 4 and alteration of gene expression profiling. We then studied methylation status and sought for mutations in altered regions on target genes. We observed methylation of DLEU7 on chromosome 13 in all patients (n = 12) with WM, and mutations of CD79B/CD79A genes (17q region), a key component of the BCR pathway, in 15% of cases. Most importantly, higher frequency of ≥3 CNA was observed in symptomatic WM. In conclusion, this study expands the view of the genomic complexity of WM, especially in symptomatic WM, including a potentially new mechanism of gene dysfunction, acquired uniparental disomy/CN-LOH. Finally, we have identified new potential target genes in WM, such as DLEU7 and CD79A/B.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23861223     DOI: 10.1002/ajh.23545

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  10 in total

1.  Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.

Authors:  C Baer; F Dicker; W Kern; T Haferlach; C Haferlach
Journal:  Leukemia       Date:  2016-11-14       Impact factor: 11.528

2.  MYD88 mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4.

Authors:  Maria Luisa Guerrera; Nickolas Tsakmaklis; Lian Xu; Guang Yang; Maria Demos; Amanda Kofides; Gloria G Chan; Robert J Manning; Xia Liu; Jiaji G Chen; Manit Munshi; Christopher J Patterson; Jorge J Castillo; Toni Dubeau; Joshua Gustine; Ruben D Carrasco; Luca Arcaini; Marzia Varettoni; Mario Cazzola; Steven P Treon; Zachary R Hunter
Journal:  Haematologica       Date:  2018-03-29       Impact factor: 9.941

3.  Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancer.

Authors:  Hemalatha Kuppusamy; Helga M Ogmundsdottir; Eva Baigorri; Amanda Warkentin; Hlif Steingrimsdottir; Vilhelmina Haraldsdottir; Michael J Mant; John Mackey; James B Johnston; Sophia Adamia; Andrew R Belch; Linda M Pilarski
Journal:  PLoS One       Date:  2014-06-20       Impact factor: 3.240

4.  Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling.

Authors:  K V Argyropoulos; R Vogel; C Ziegler; G Altan-Bonnet; E Velardi; M Calafiore; A Dogan; M Arcila; M Patel; K Knapp; C Mallek; Z R Hunter; S P Treon; M R M van den Brink; M L Palomba
Journal:  Leukemia       Date:  2016-02-12       Impact factor: 11.528

Review 5.  Waldenstrom's Macroglobulinemia: An Update.

Authors:  Maddalena Mazzucchelli; Anna Maria Frustaci; Marina Deodato; Roberto Cairoli; Alessandra Tedeschi
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-01-01       Impact factor: 2.576

6.  From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation.

Authors:  C Jiménez; S Alonso-Álvarez; M Alcoceba; G R Ordóñez; M García-Álvarez; M I Prieto-Conde; M C Chillón; A Balanzategui; R Corral; L A Marín; N C Gutiérrez; N Puig; M E Sarasquete; M González; R García-Sanz
Journal:  Blood Cancer J       Date:  2017-08-25       Impact factor: 11.037

7.  The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom's Macroglobulinemia.

Authors:  Collin K Chin; Connull Leslie; Carolyn S Grove; Chris Van Vliet; Chan Yoon Cheah
Journal:  Int J Mol Sci       Date:  2017-09-22       Impact factor: 5.923

8.  Synergistic cooperation and crosstalk between MYD88L265P and mutations that dysregulate CD79B and surface IgM.

Authors:  James Q Wang; Yogesh S Jeelall; Peter Humburg; Emma L Batchelor; Sarp M Kaya; Hee Min Yoo; Christopher C Goodnow; Keisuke Horikawa
Journal:  J Exp Med       Date:  2017-07-12       Impact factor: 14.307

9.  BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia.

Authors:  Charles Herbaux; Elisabeth Bertrand; Guillemette Marot; Christophe Roumier; Nicolas Poret; Valérie Soenen; Olivier Nibourel; Catherine Roche-Lestienne; Natacha Broucqsault; Sylvie Galiègue-Zouitina; Eileen M Boyle; Guillemette Fouquet; Aline Renneville; Sabine Tricot; Franck Morschhauser; Claude Preudhomme; Bruno Quesnel; Stephanie Poulain; Xavier Leleu
Journal:  Oncotarget       Date:  2016-06-07

Review 10.  Time to Move to the Single-Cell Level: Applications of Single-Cell Multi-Omics to Hematological Malignancies and Waldenström's Macroglobulinemia-A Particularly Heterogeneous Lymphoma.

Authors:  Ramón García-Sanz; Cristina Jiménez
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.